LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 54

Search options

  1. Article: Scoring microvascular invasion in hepatocellular carcinoma: are we meeting the grade?

    Erstad, Derek J / Tanabe, Kenneth K

    Hepatobiliary surgery and nutrition

    2024  Volume 13, Issue 1, Page(s) 184–187

    Language English
    Publishing date 2024-01-18
    Publishing country China (Republic : 1949- )
    Document type Editorial
    ZDB-ID 2812398-0
    ISSN 2304-389X ; 2304-3881
    ISSN (online) 2304-389X
    ISSN 2304-3881
    DOI 10.21037/hbsn-23-50
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: ASO Author Reflections: Amputation for Extremity Sarcoma.

    Erstad, Derek J

    Annals of surgical oncology

    2018  Volume 26, Issue Suppl 3, Page(s) 548

    MeSH term(s) Amputation/statistics & numerical data ; Amputation/trends ; Extremities/pathology ; Humans ; Prognosis ; Sarcoma/pathology ; Sarcoma/surgery
    Language English
    Publishing date 2018-12-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-018-7069-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials.

    Witt, Russell G / Erstad, Derek J / Wargo, Jennifer A

    Therapeutic advances in medical oncology

    2022  Volume 14, Page(s) 17588359221083052

    Abstract: The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite ... ...

    Abstract The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite improvements in patient response rates and survival with these new treatments, there exists a large portion of patients with surgically resectable disease that are high risk for relapse. Patients with high-risk resectable melanoma account for up to 20% of newly diagnosed cases. For this high-risk group of patients, neoadjuvant therapy has many purposed advantages over adjuvant therapy, including a more robust immune response due to abundant tumor antigens at treatment initiation, the ability to assess pathologic response to therapy, tumor downstaging leading to increased disease resectability, and a potential decreased need for extensive lymphadenectomies. These findings have been backed by preclinical models and multiple neoadjuvant trials are underway. In this review, we will discuss the trials that have set the foundation for the current treatment standards and discuss the role and rationale for neoadjuvant therapy for high-risk malignant melanomas.
    Language English
    Publishing date 2022-03-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359221083052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Neoadjuvant therapy for melanoma: new and evolving concepts.

    Erstad, Derek J / Witt, Russell G / Wargo, Jennifer A

    Clinical advances in hematology & oncology : H&O

    2022  Volume 20, Issue 1, Page(s) 47–55

    Abstract: Effective systemic therapies, including targeted BRAF/MEK inhibition and immune checkpoint blockade, have significantly changed the treatment landscape for malignant melanoma. Specifically, there have been promising clinical trial findings associated ... ...

    Abstract Effective systemic therapies, including targeted BRAF/MEK inhibition and immune checkpoint blockade, have significantly changed the treatment landscape for malignant melanoma. Specifically, there have been promising clinical trial findings associated with the use of neoadjuvant therapy for clinically node-positive and oligometastatic disease, conditions that have historically been managed with up-front surgical resection when possible. This review focuses on the burgeoning field of neoadjuvant therapy for melanoma. We review the rationale for this treatment approach, summarize completed and ongoing neoadjuvant clinical trials, and contextualize these findings within the growing body of knowledge about targeted and immune checkpoint therapy. Finally, we discuss future directions for neoadjuvant trials in melanoma, with particular focus on biomarker development, treatment effect modification, novel therapeutic regimens, and evolving surgical indications for regional and oligometastatic disease.
    MeSH term(s) Humans ; Melanoma/drug therapy ; Neoadjuvant Therapy ; Skin Neoplasms/drug therapy
    Language English
    Publishing date 2022-01-19
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma.

    Erstad, Derek J / Tanabe, Kenneth K

    Annals of surgical oncology

    2019  Volume 26, Issue Suppl 3, Page(s) 617–618

    MeSH term(s) Carcinoma, Hepatocellular/surgery ; Hepatectomy ; Humans ; Liver Neoplasms/surgery ; Prognosis
    Language English
    Publishing date 2019-05-20
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-019-07364-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: An angiotensin system inhibitor (losartan) potentiates antitumor efficacy of cisplatin in a murine model of non-small cell lung cancer.

    Tang, Hexiao / Abston, Eric / Sojoodi, Mozhdeh / Wang, Yongtao / Erstad, Derek J / Lin, Zenan / Fuchs, Bryan C / Tanabe, Kenneth K / Lanuti, Michael

    JTCVS open

    2024  Volume 18, Page(s) 306–321

    Abstract: Objective: Previous studies have demonstrated synergistic antitumor effects of angiotensin system inhibition (ASI) combined with cisplatin therapy in pancreatic cancer. This study examines whether or not synergistic antitumor effects occur with ... ...

    Abstract Objective: Previous studies have demonstrated synergistic antitumor effects of angiotensin system inhibition (ASI) combined with cisplatin therapy in pancreatic cancer. This study examines whether or not synergistic antitumor effects occur with combination ASI and cisplatin treatment in lung cancer, and whether or not ASI-induced changes in epithelial-mesenchymal transition play a role in the mechanism of this antitumor phenomenon.
    Methods: A set of lung cancer cell lines representing a spectrum of epithelial to mesenchymal phenotypes were identified and characterized. Response of epithelial-mesenchymal transition markers to losartan was characterized. Cell culture models of lung cancer were next treated with losartan, cisplatin, or combination of both. Markers of epithelial-mesenchymal transition or surrogates of other signaling pathways (AKT, Stat3, and programmed death-ligand), and cell viability were quantified. Findings were confirmed in both allogenic and syngeneic in vivo murine flank tumor models.
    Results: Losartan treatment significantly increased E-cadherin and reduced vimentin in human lung cancer cell lines. Combination treatment with losartan and cisplatin enhanced epithelial markers, reduced mesenchymal markers, inhibited promesenchymal signaling mediators, and reduced cell viability. Findings were confirmed in vivo in a murine flank tumor model with transition from mesenchymal to epithelial phenotype and reduced tumor size following combination losartan and cisplatin treatment.
    Conclusions: Combination losartan and cisplatin treatment attenuates the epithelial-mesenchymal transition pathway and enhances the cytotoxic effect of chemotherapy with in vitro and in vivo models of non-small cell lung cancer. This study suggests an important role for ASI therapy in the treatment of lung cancer.
    Language English
    Publishing date 2024-02-01
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2666-2736
    ISSN (online) 2666-2736
    DOI 10.1016/j.xjon.2024.01.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma.

    Erstad, Derek J / Tanabe, Kenneth K

    Annals of surgical oncology

    2019  Volume 26, Issue 5, Page(s) 1474–1493

    Abstract: Hepatocellular carcinoma (HCC) is a morbid condition for which surgical and ablative therapy are the only options for cure. Nonetheless, over half of patients treated with an R0 resection will develop recurrence. Early recurrences within 2 years after ... ...

    Abstract Hepatocellular carcinoma (HCC) is a morbid condition for which surgical and ablative therapy are the only options for cure. Nonetheless, over half of patients treated with an R0 resection will develop recurrence. Early recurrences within 2 years after resection are thought to be due to the presence of residual microscopic disease, while late recurrences > 2 years after resection are thought to be de novo metachronous HCCs arising in chronically injured liver tissue. Microvascular invasion (MVI) is defined as the presence of micrometastatic HCC emboli within the vessels of the liver, and is a critical determinant of early recurrence and survival. In this review, we summarize the pathogenesis and clinical relevance of MVI, which correlates with adverse biological features, including high grade, large tumor size, and epithelial-mesenchymal transition. Multiple classification schemas have been proposed to capture the heterogeneous features of MVI that are associated with prognosis. However, currently, MVI can only be determined based on surgical specimens, limiting its clinical applicability. Going forward, advances in axial imaging technologies, molecular characterization of biopsy tissue, and novel serum biomarkers hold promise as future methods for non-invasive MVI detection. Ultimately, MVI status may be used to help clinicians determine treatment plans, particularly with respect to surgical intervention, and to provide more accurate prognostication.
    MeSH term(s) Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/surgery ; Hepatectomy/methods ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms/surgery ; Microvessels/pathology ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/surgery ; Prognosis
    Language English
    Publishing date 2019-02-20
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-019-07227-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Amputation for Sarcoma: Revisiting a 19th Century Treatment in the 21st Century.

    Erstad, Derek J / Raut, Chandrajit P

    Annals of surgical oncology

    2017  Volume 25, Issue 2, Page(s) 351–353

    MeSH term(s) Amputation/history ; History, 19th Century ; History, 20th Century ; History, 21st Century ; Humans ; Sarcoma/surgery ; Surgical Oncology/history
    Language English
    Publishing date 2017-11-27
    Publishing country United States
    Document type Editorial ; Historical Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-017-6243-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Hepatocellular carcinoma: early-stage management challenges.

    Erstad, Derek J / Tanabe, Kenneth K

    Journal of hepatocellular carcinoma

    2017  Volume 4, Page(s) 81–92

    Abstract: Hepatocellular carcinoma (HCC) is a major cause of cancer death and is increasing in incidence. This review focuses on HCC surveillance and treatment of early-stage disease, which are essential to improving outcomes. Multiple societies have published HCC ...

    Abstract Hepatocellular carcinoma (HCC) is a major cause of cancer death and is increasing in incidence. This review focuses on HCC surveillance and treatment of early-stage disease, which are essential to improving outcomes. Multiple societies have published HCC surveillance guidelines, but screening efforts have been limited by noncompliance and overall lack of testing for patients with undiagnosed chronic liver disease. Treatment of early-stage HCC has become increasingly complex due to expanding therapeutic options and better outcomes with established treatments. Surgical indications for HCC have broadened with improved preoperative liver testing, neoadjuvant therapy, portal vein embolization, and perioperative care. Advances in post-procedural monitoring have improved efficacies of transarterial chemoembolization and radiofrequency ablation, and novel therapies involving delivery of radiochemicals are being studied in small trials. Finally, advances in liver transplantation have allowed for expanded indications beyond Milan criteria with non-inferior outcomes. More clinical trials evaluating new therapies and multimodal regimens are necessary to help clinicians design better treatment algorithms and improve outcomes.
    Language English
    Publishing date 2017-06-23
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2780784-8
    ISSN 2253-5969
    ISSN 2253-5969
    DOI 10.2147/JHC.S107370
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Abdominal Pain After Colonoscopy.

    Erstad, Derek J / Krowsoski, Leandra S / Kaafarani, Haytham M A

    Gastroenterology

    2017  Volume 152, Issue 3, Page(s) 486–487

    Language English
    Publishing date 2017-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2016.08.060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top